Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma

Ki Hyang Kim, Sang Hyun Yoon, Hae Jung Lee, Hyo Song Kim, Sang Joon Shin, Joong Bae Ahn, Sun Young Rha

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Few studies have investigated the effects of everolimus therapy in Asian populations. This study evaluates the safety and efficacy of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC). Methods: We retrospectively reviewed records of Korean patients with mRCC (n = 22) who received everolimus between January 2009 and July 2010 and evaluated them for efficacy and safety. Results: One patient achieved a partial response, and 16 patients had stable disease, corresponding to an overall response rate of 4.5 % and a disease control rate of 77.3 %. Median progression-free survival was 5.4 months (95 % CI 0.9-9.8). Median overall survival was not reached. Univariate analysis showed that Memorial Sloan-Kettering Cancer Center risk (P =.004), thrombocytopenia (P =.018), hyperglycemia (P =.007) and hypertriglyceridemia (P =.041) were associated with disease progression. The most common adverse events (AEs) were hypertriglyceridemia and anemia, similar to Western patients. Creatinine and aspartate aminotransferase levels were higher than those reported for Western patients. The most common grade ≥3 AEs in this study were hypertriglyceridemia and anemia, compared with lymphopenia (14 %) in Western patients. Conclusions: Safety of everolimus in Korean mRCC patients differed from that reported in Western patients. Therefore, liver function enzymes, hemoglobin levels, lipid profile and chest CT scans should be monitored more closely in Asian mRCC patients receiving everolimus.

Original languageEnglish
Pages (from-to)853-860
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume72
Issue number4
DOIs
Publication statusPublished - 2013 Oct 1

Fingerprint

Renal Cell Carcinoma
Cells
Safety
Hypertriglyceridemia
Disease control
Computerized tomography
Aspartate Aminotransferases
Liver
Anemia
Creatinine
Hemoglobins
Everolimus
Lipids
Lymphopenia
Enzymes
Hyperglycemia
Thrombocytopenia
Disease-Free Survival
Disease Progression
Thorax

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Kim, Ki Hyang ; Yoon, Sang Hyun ; Lee, Hae Jung ; Kim, Hyo Song ; Shin, Sang Joon ; Ahn, Joong Bae ; Rha, Sun Young. / Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. In: Cancer Chemotherapy and Pharmacology. 2013 ; Vol. 72, No. 4. pp. 853-860.
@article{52ffb2a0d3644ef1bc80fdf84227bb46,
title = "Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma",
abstract = "Purpose: Few studies have investigated the effects of everolimus therapy in Asian populations. This study evaluates the safety and efficacy of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC). Methods: We retrospectively reviewed records of Korean patients with mRCC (n = 22) who received everolimus between January 2009 and July 2010 and evaluated them for efficacy and safety. Results: One patient achieved a partial response, and 16 patients had stable disease, corresponding to an overall response rate of 4.5 {\%} and a disease control rate of 77.3 {\%}. Median progression-free survival was 5.4 months (95 {\%} CI 0.9-9.8). Median overall survival was not reached. Univariate analysis showed that Memorial Sloan-Kettering Cancer Center risk (P =.004), thrombocytopenia (P =.018), hyperglycemia (P =.007) and hypertriglyceridemia (P =.041) were associated with disease progression. The most common adverse events (AEs) were hypertriglyceridemia and anemia, similar to Western patients. Creatinine and aspartate aminotransferase levels were higher than those reported for Western patients. The most common grade ≥3 AEs in this study were hypertriglyceridemia and anemia, compared with lymphopenia (14 {\%}) in Western patients. Conclusions: Safety of everolimus in Korean mRCC patients differed from that reported in Western patients. Therefore, liver function enzymes, hemoglobin levels, lipid profile and chest CT scans should be monitored more closely in Asian mRCC patients receiving everolimus.",
author = "Kim, {Ki Hyang} and Yoon, {Sang Hyun} and Lee, {Hae Jung} and Kim, {Hyo Song} and Shin, {Sang Joon} and Ahn, {Joong Bae} and Rha, {Sun Young}",
year = "2013",
month = "10",
day = "1",
doi = "10.1007/s00280-013-2266-y",
language = "English",
volume = "72",
pages = "853--860",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. / Kim, Ki Hyang; Yoon, Sang Hyun; Lee, Hae Jung; Kim, Hyo Song; Shin, Sang Joon; Ahn, Joong Bae; Rha, Sun Young.

In: Cancer Chemotherapy and Pharmacology, Vol. 72, No. 4, 01.10.2013, p. 853-860.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma

AU - Kim, Ki Hyang

AU - Yoon, Sang Hyun

AU - Lee, Hae Jung

AU - Kim, Hyo Song

AU - Shin, Sang Joon

AU - Ahn, Joong Bae

AU - Rha, Sun Young

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Purpose: Few studies have investigated the effects of everolimus therapy in Asian populations. This study evaluates the safety and efficacy of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC). Methods: We retrospectively reviewed records of Korean patients with mRCC (n = 22) who received everolimus between January 2009 and July 2010 and evaluated them for efficacy and safety. Results: One patient achieved a partial response, and 16 patients had stable disease, corresponding to an overall response rate of 4.5 % and a disease control rate of 77.3 %. Median progression-free survival was 5.4 months (95 % CI 0.9-9.8). Median overall survival was not reached. Univariate analysis showed that Memorial Sloan-Kettering Cancer Center risk (P =.004), thrombocytopenia (P =.018), hyperglycemia (P =.007) and hypertriglyceridemia (P =.041) were associated with disease progression. The most common adverse events (AEs) were hypertriglyceridemia and anemia, similar to Western patients. Creatinine and aspartate aminotransferase levels were higher than those reported for Western patients. The most common grade ≥3 AEs in this study were hypertriglyceridemia and anemia, compared with lymphopenia (14 %) in Western patients. Conclusions: Safety of everolimus in Korean mRCC patients differed from that reported in Western patients. Therefore, liver function enzymes, hemoglobin levels, lipid profile and chest CT scans should be monitored more closely in Asian mRCC patients receiving everolimus.

AB - Purpose: Few studies have investigated the effects of everolimus therapy in Asian populations. This study evaluates the safety and efficacy of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC). Methods: We retrospectively reviewed records of Korean patients with mRCC (n = 22) who received everolimus between January 2009 and July 2010 and evaluated them for efficacy and safety. Results: One patient achieved a partial response, and 16 patients had stable disease, corresponding to an overall response rate of 4.5 % and a disease control rate of 77.3 %. Median progression-free survival was 5.4 months (95 % CI 0.9-9.8). Median overall survival was not reached. Univariate analysis showed that Memorial Sloan-Kettering Cancer Center risk (P =.004), thrombocytopenia (P =.018), hyperglycemia (P =.007) and hypertriglyceridemia (P =.041) were associated with disease progression. The most common adverse events (AEs) were hypertriglyceridemia and anemia, similar to Western patients. Creatinine and aspartate aminotransferase levels were higher than those reported for Western patients. The most common grade ≥3 AEs in this study were hypertriglyceridemia and anemia, compared with lymphopenia (14 %) in Western patients. Conclusions: Safety of everolimus in Korean mRCC patients differed from that reported in Western patients. Therefore, liver function enzymes, hemoglobin levels, lipid profile and chest CT scans should be monitored more closely in Asian mRCC patients receiving everolimus.

UR - http://www.scopus.com/inward/record.url?scp=84885371769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885371769&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2266-y

DO - 10.1007/s00280-013-2266-y

M3 - Article

C2 - 23978988

AN - SCOPUS:84885371769

VL - 72

SP - 853

EP - 860

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -